## **Total Body Irradiation**

Subhashini John

# Total Body Irradiation (TBI)




1905 Dessauer - "X-ray bath" **Chaoul & Lange - Lymphomas** 1923 1920s Animal experiments to determine biological effects "Heublein therapy", New York 1931 1930s-40s Used for nearly every malignant disease - Limited success 1942 Medinger & Craver reviewed 270 cases treated at Memorial between 1931-1940

## **Total Body Irradiation (TBI) History**

Early 1950s : Introduction of chemotherapy

- TBI declined
- 1954 Barnes & Loutit Observed immune response after TBI in animals
- 1955-56 1957-
- TBI & BMT in animals
  - TBI & BMT in humans
    - Leukemias
    - Aplastic anemia
    - Ewing's sarcoma
    - Others



#### **Total Body Irradiation (TBI) History**

- 1970 Pioneering work of Donald Thomas in Seattle
  - Proved usefulness of TBI
  - Increasing use and demand for TBI
- Dedicated equipment costly
- Modified standard Megavoltage RT equipment developed – less expensive

#### Total Body Irradiation (TBI) History

- Rationale for use of TBI not changed
- Tremendous change in
  - Delivery of TBI
  - Radiation sources used Co60/ Linac

 Dose measurement techniques - more reliable and accurate rather than erythema dose for determination of dose delivered

#### Indications for TBI

- Acute Leukemia ALL, AML
- Chronic Leukemia CML
- Myelodysplastic Syndromes
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Aplastic Anemia
- Autoimmune Diseases

## ACR Practice Guidelines for the performance of TBI (Revised 2006)

Describes a quality assurance program for TBI

Supplementary to the ACR Practice Guideline for Radiation Oncology & the ACR Technical Standard for the Performance of Radiation Oncology Physics for External Beam Therapy

#### Introduction

Prior to transplantation of hematopoietic stem cells or peripheral blood progenitor stem cells, when Combined with intensive Chemotherapy TBI enables – Myeloablative high dose therapy

Immuno-ablative conditioning treatment

#### Tasks of TBI

- Immunosuppression lymphocyte elimination to allow grafting of donor bone marrow
- Eradication of malignant cells leukemia, lymphoma, rarely solid tumors
- Eradication of cells with genetic disorders -Fanconi's anemia, thalassemia major, Wiskott - Aldritch syndrome

#### Unique features of TBI

Valuable component of transplant preparative regimens vs chemotherapy

- 1. No sparing of "sanctuary" sites (testes, brain)
- 2. Dose homogeneity regardless of blood supply
- 3. No known cross-resistance with other agents
- 4. No problems with excretion or detoxification
- 5. Ability to tailor the dose distribution by shielding specific organs or by "boosting" sites

#### Interventions and Practices Considered

1. Process of Total body irradiation (TBI)

- Clinical evaluation
- Obtaining informed consent
- Treatment planning
- Simulation of treatment
- Dose calculations
- Treatment delivery and treatment aids

#### Interventions and Practices Considered

- 2. Qualifications & responsibilities of personnel
- 3. Patient and personnel safety measures
- 4. Types of equipment needed
- 5. Documentation
- 6. Continuing medical education programs for medical staff
- 7. Quality control and improvement & patient education

#### **Clinical Evaluation**

- Detailed history issues that may impact upon treatment tolerance
  - Previous radiotherapy to sensitive organs
  - Factors affecting pulmonary, renal or hepatic function
  - Exposure to infectious agents
- Physical examination
- Review of all pertinent diagnostic and laboratory tests

#### **Clinical Evaluation**

- Communication with the referring physician and other physicians involved in the patient's care in accordance with the ACR Practice Guideline for Communication: Radiation Oncology
- Careful review of the applicable protocol for the particular disease being treated is essential since standardized institutional or cooperative group protocols are the norm for transplantation

#### Informed Consent

- Prior to simulation and treatment, informed consent must be obtained and documented and must be in compliance with applicable laws, regulations, or policies
- Detailed discussion of
  - Benefits
  - Potential tissue-specific acute and late toxicities
  - Details of, rationale for, and alternatives to TBI

#### **Treatment Planning**

#### **Specific treatment parameters**

- field size
- dose per fraction, dose rate, total dose, fractions per day, interval between fractions
- if relevant, beam energy, geometry to achieve dose homogeneity
- bolus or beam spoilers to increase skin dose
- shielding and dose compensation requirements (e.g., lungs, kidneys)
- boost specifications (e.g., testes)

#### **Treatment Planning**

#### Specific treatment parameters contd

Patient thickness measurements at

- The prescription point (often at the level of the umbilicus)

- Other points of interest for dose calculations and homogeneity determinations - head, neck, midmediastinum, mid-lung, pelvis, knee, ankle, etc.

 Patient height - to determine the appropriate sourceto-patient distance to appropriately fit the patient within the beam with sufficient margin around the patient (>5 cm, usually)

#### Simulation

- For lung or other organ blocking, simulation or other treatment planning is generally done in the treatment position
- If the planning session is performed in another position, positional differences in organ location should be taken into account, and the medical physicist should be consulted
- Reference points for block placement at the time of treatment should be marked on the patient's body for reproducibility

#### Calculation

- Medical physicist to achieve the prescribed dose, dose homogeneity in locations specified by protocol & doses at any other points of concern
- A second medical physicist independently checks the calculation before the first fraction
- In vivo dosimetry may aid in assessment of dose homogeneity
- Every effort should be made to maintain dose inhomogeneity to within +/-10%

#### **Treatment Aids**

Special TBI stands or tables are often
used to aid in
Immobilization
Placement of organ shields
Patient support and comfort

#### **Treatment Delivery**

- Fractionated or hyperfractionated regimens (twice a day or three times a day) in order to
  - Minimize both acute and chronic toxicities
  - Minimize overall treatment time
- Prior to treatment, any shielding of normal organs should be checked with portal images
- In the setting of single fraction low-dose TBI, total doses are typically only 200 cGy, organ shielding is not utilized

#### **Treatment Delivery**

- Dosimetry should be checked against department protocols to verify dose delivery at the extended distances that are usually used for treatment
- A medical physicist should be available during all treatments in case of questions regarding
  - -dosimetric details
  - -equipment function
  - -patient setup, etc.
- Treatments are carried out by the radiation therapist per the ACR Practice Guideline for Radiation Oncology

#### Qualifications & Responsibilities of Personnel

Application of this guideline should be in accordance with the ACR Practice Guideline for Radiation Oncology

- Radiation Oncologist
- Qualified Medical Physicist
- Dosimetrist
- Nurse


## Equipment

- High-energy photon beams
  - Linear accelerators in the range of 4-18 MV or
  - Co-60 unit
- Additional equipment may include a fluoroscopy or computed tomography (CT) simulator
- Immobilization devices
- Equipment to fabricate shielding blocks

## Equipment

- Computers for dose calculations
- Beam spoiler
- Custom bolus, Custom compensators
- Dosimetry and calibration devices
- A backup beam delivery system must be available in case of unanticipated machine failure

#### **Bone Marrow Transplant Procedure**



## Total Body Irradiation Intent & Dose

#### Low dose TBI

- No transplant, generate immune response
- Lymphocytic leukemia, lymphoma, neuroblastoma
- Total dose of 100-150 cGy in 10-15 fractions

## Total Body Irradiation Intent & Dose

#### High dose TBI

- Intent
  - Preparatory for bone marrow transplant
    - Leukemia, myeloma, lymphoma, aplastic anemia
  - Kill tumour cells, Reduce immune response
- Dose
  - Single Fraction
    - 500 to 900 cGy
  - Fractionated
    - 1200 cGy in 2 # over 2 days
    - 1200 cGy in 6 # over 3 days (2#/day)

#### Advantages of Fractionated TBI

#### Most Common schedule

- 1200cGy in 6 Fractions over 3 days
  - dose/ Fractions =200cGy
  - Separated by minimum six hours
- Less side effects during treatment
- Lesser probability of pulmonary complications
- Generally maintains a high imunosuppressive effect
- Improves the therapeutic ratio

#### **TBI Requirements - Clinical**

- Dose Prescription point
   Intersection point of Line 1 and 2


   Line 1 intersection between the midsagittal and midaxial planes
   Line 2 intersection between the mid
  - corronal and mid axial planes

#### **TBI Requirements - Clinical**

- Required dose uniformity ± 5%
- Realistic ± 10%
- Low dose rate
- Less dose to Lung

   < 700 cGy for single fraction of 900cGy</li>
   < 950cGy for 2 fractions of 600cGy (1200cGy)</li>
   <14Gy for fractionated TBI</li>

## Compensators for improved Homogeneous Dose



#### **TBI Requirements - Physical**

- Treatment Unit
  - Dedicated unit
  - Modified Conventional Machines
- Beam Energy
  - Mega-voltage (Cobalt unit or Linac)
- Field size 50 x 200 cm<sup>2</sup>
- SSD 200 cm to 400 cm


#### **TBI Requirements - Physical**

#### Technique

- Parallel opposed (AP-PA or Lateral)
- Shielding
  - Partial lung shielding (1 HVL)
  - Kidney & liver may require shielding


#### Dose Rate

Average 8 to 10 cGy / minute Maximum up to 15 cGy)




#### **Radiation Pneumonitis**

- Major concern for whole lung irradiation
  - Especially TBI and HBI



 Factors affecting lung dose



#### **TBI Treatment Variables**

- Machine (Energy-Co60,4MV,6MV,10MV)
- Total Dose
- Fractionation
- Dose Rate
- Prescription point
- Compensators or bolus



## **TBI Treatment Variables**

- Treatment fields: AP-PA, laterals, AP-PA sweep, combination, others
- SSD
  - Vertical 150-200 cm
  - Horizontal 240-550 cm



### **TBI Techniques**


**Dedicated Machines** 

Single, dual & multiple sources
Track mounted mobile sources
Specially designed flattening filter
Max. field size of 75×210cm<sup>2</sup>


## **TBI Techniques**

Modified Conventional Machines -Large Stationary Beam, Stationary Patient - Extended SSD Technique - Collimator removal method Moving Beams produced by 2,7 -Translational beam method - Sweeping beam TBI

# **TBI-Irradiation Methods**



# Princess Margaret Hospital (PMH), Toronto - Hemitron







Princess Margaret Hospital, Toronto

#### Hemitron


Cobalt-60
 80×250 cm<sup>2</sup>
 0 150 cm



# McGill University Sweeping Beam Technique



# **TBI: McGill Technique**



# McGill University Sweeping Beam Technique



#### **Translational Couch**




**Computer controlled** 


## The Utrecht TBI Chair




- Devoloped at the University Hospital of Utrecht
- To have equal sagittal thickness both in trunk and legs
- Perspex attenuators to guarantee maximum skin dose

### Isocentrically mounted stand






# Lateral on Couch – extended SSD



# TBI at Vellore – Lateral Couch extended SSD



# TBI – Commissioning measurements at CMC, Vellore

- Choice of Unit & energy
  - Linac & 6 MV beam
- Output Calibration at Extended SSD
- Beam profiles measurement for the extended SSD
- Measurement of depth dose (PDD/TMR)

# TBI – Commissioning measurements at CMC, Vellore

- Skin dose
  - choice of beam spoiler position & thickness
- Calibration of Diodes for in vivo dosimetry at Treatment conditions
- Preparation of Protocol for patient positioning
- Measurement of attenuation coeff for aluminium and perspex to be used as tissue compensator

# Beam spoiler to enhance surface dose



# Output Measurement at extended SSD (at D<sub>max)</sub>

#### Dosimeter

- SSD meter Capintec
   .6cc farmer chamber
- Phantom
  - Perspex
- Beam spoiler
  - 1cm perspex
- Protocol IAEA TRS 398
- SSD = 385 cm



## **Beam Profile Measurement**

#### • Detector

- PTW Diodes 8 nos
- Placed 10 cm apart
- Profile for 150 cm measured by moving the diodes by 5 cm.
- Acrylic sheets used as back scatter material
- Profile measured at SSD 385cm




#### Verification of the Beam Profile



The patient setup is simulated with perspex sheets

#### Profile at extended SSD with Beam spoiler




# Percentage Depth dose at extended SSD


#### Dosimeter

- SSD meter Capintec .6cc farmer chamber
- Phantom
  - Perspex
- Beam spoiler
  - 1cm perspex
- Chamber placed at different depths
- SSD = 385 cm



## Percentage Depth Dose at Extended SSD





### Calibration of Diodes for In vivo-Dosimetry

- PTW diodes were placed at the middle of the phantom
- Exposed to known dose at D<sub>max</sub>
- Calibration factor determined for each diode



# TBI Treatment Protocol CMC Vellore

- Day 5
  - Set-up measurements
  - Measurements of separation of different regions
- Day 4
  - Calculation of attenuator thickness & MU
- Day 3
  - TBI first fraction with in-vivo dosimetry (AM)
- Verification of Attenuator thickness
  - TBI second fraction with corrected attenuator thickness (if required)

# TBI Treatment Protocol CMC Vellore.


#### Day – 5: Patient Setup and Positioning Measurements

	Patient Na	ame:	Patient No:	
1	Position th	ne height of linac couch	121	cm
2	Collimato	r angle	45	0
3	Gantry an	gle	90	0
5	Measure <sub>1</sub>	patient length	135	cm
6	Fix source	e to surface distance (SSD)	285	cm
7	Check the	e patient with light beam		
8	Place the	Diodes		
9	Measure (	he distance		
	Ι	EAM level	298	cm
	II	Centre level	285	cm
	III	Knee level	294.4	cm
	IV	Ankle level	298.5	cm
10	Distance between beam spoiler and isocenter		254	cm


# **Measurement of Separations**

Day – 5				
Regions	Separation (cm)			
Skull	15.50			
Neck	11.00			
Shoulder	45.00			
Chest	31.00			
Center	35.00			
Thigh	32.00			
Knee	21.00			
Calf	20.50			
Ankle	13.50			

Dov



#### **Compensator Thickness**



## Calculation of Compensator Thickness

Day - 4

<b>S</b> 1.	Position	PDD	Mid Plane	Thickness of	Thickness of
No	1 OSITION	TDD	Dose (cGy)	Aluminium	Perspex (cm)
1	Skul1	85.8	129.02	26.8	4.7
2	Neck	90.5	136.09	32.4	5.7
3	Shoulder	50.5	75.94	-29.0	-5.0
4	Chest	66.5	100.00	0.0	0.0
5	Umblicus (Center	66.5	100.00	0.0	0.0
6	Thigh	69	103.76	3.9	0.7
7	Knee	73.5	110.53	10.5	1.8
8	Calf	75.5	113.53	13.4	2.3
9	Ankle	88	132.33	29.5	5.1

#### Treatment setup - check sheet

#### Day - 3

	Patient Name:		Defect Mer		Date	
			Patient No:	Patient No:		A/N
1	Position the height of linac couch		121	cm		
2	Collimator	r angle	45	0		
3	Gantry an	gle	90	0		
4	Measure p	patient length	135	cm		
5	Fix isocen	tre to surface distance (SSD)	285	cm		
б	Check the	e patient with light beam				
7	Place the 3	Diodes				
8	Measure t	he distance				
	Ι	EAM level	298	cm		
	II	Centre level	285	cm		
	III	Knee level	294.4	cm		
	IV	Ankle level	298.5	cm		
9	Distance between beam spoiler and isocenter		254	cm		
10	Place the compensators					
	Ι	Head	4.70	cm		
	II	Neck	5.70	cm		
	III	Knee	10.53	mm		
	IV	Calf	13.36	mm		
	V	Ankle	29.49	mm		

# Day – 3 Patient Positioning



- 40 x 40 cm Field Size, Gantry 90°
- SSD 385 cm, Measurements

#### In-vivo Dosimetry with Diodes Day – 3



 Image: state stat

**Diodes placed on patient** 

**On-line dosimetry** 

Dose Guided Radiotherapy (DGRT)!!!!!!

# In-Vivo Measurements

REGION	MID PLANE DOSE					
REGION	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	
Skull	92.5	102.7	90.8	99.3	97.0	
Neck	102.2	97.7	93.7	87.6 +	101.1	
Chest	104.9	98.6	98.0	100.6	89.6	
Umbilicus	100.0	100.0	100.0	100.0	100.0	
Thigh	98.4	104.4	106.6	98.5	102.2	
Knee	90.7	94.9	91.9	94.5	95.7	
Calf	93.1	91.2	95.4	92.3	91.9	
Ankle	109.6	100.8	95.4	101.1	98.0	

#### Acute Complications of TBI

- Mucositis
- Hair loss
- Bone marrow suppression
- Veno-occlusive disease of liver
- Interstitial pneumonitis
- GI toxicity

#### **Chronic Complications of TBI**

- Pulmonary
   Destrictive
  - Restrictive disease (8%) Alteration in DLCO (12%)
- Ocular (29.5%) cataract, dryness, keratitis
- Thyroid Hypothyroidism, thyroiditis, Basedow's disease
- Infertility
- Secondary malignancies
- Radiation nephropathy

# Acknowledgements

- Dr Paul Ravindran
- Dr Rajesh B
- Dr Rajesh I

